Need help finding what you are looking for?
Contact Us
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223476
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223476
Global Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030
PUBLISHED:
PAGES: 700 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
The global pancreatic cancer diagnostics market is projected to register a substantial CAGR of 7.5% from 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030.
Market Segmentation:
Global Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type(Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application(Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland and the Rest of Europe, China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan and the Rest of Asia-Pacific, South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel and the Rest of Middle East and Africa, Brazil, Argentina, and the Rest of South America) Industry Trends and Forecast to 2030.
Some of the major factors contributing to the growth of global pancreatic cancer diagnostics market are:
Rise in prevalence and incidence of pancreatic cancer
Increase in awareness about the pancreatic cancer diagnostics
Market Players:
Some of the major players operating in the global pancreatic cancer diagnostics market are:
Canon Medical Systems ANZ Pty Limited.
Koninklijke Philips N.V.
Siemens Healthcare Private Limited
Grail
Myriad Genetics, Inc.
BD
Boditech Med Inc.
Abbott
FUJIFILM Holdings America Corporation
Agilent Technologies, Inc.
Thermo Fisher Scientific
QIAGEN
MP BIOMEDICALS
Laboratory Corporation of America Holdings
CTK Biotech, Inc.
AccuBioTech Co., Ltd.
DiaSource
Setia Scientific Solution
Creative Biolabs
Meridian Life Science, Inc.
Lee Biosolutions, Inc
TABLE OF CONTENTS
1 INTRODUCTION 92
- 1.1 OBJECTIVES OF THE STUDY 92
- 1.2 MARKET DEFINITION 92
- 1.3 OVERVIEW OF THE GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET 92
- 1.4 CURRENCY AND PRICING 95
- 1.5 LIMITATIONS 95
- 1.6 MARKETS COVERED 95
2 MARKET SEGMENTATION 99
- 2.1 MARKETS COVERED 99
- 2.2 GEOGRAPHICAL SCOPE 100
- 2.3 YEARS CONSIDERED FOR THE STUDY 101
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 102
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 105
- 2.6 MULTIVARIATE MODELLING 106
- 2.7 MARKET END USER COVERAGE GRID 107
- 2.8 PRODUCT LIFELINE CURVE 108
- 2.9 DBMR MARKET POSITION GRID 109
- 2.10 VENDOR SHARE ANALYSIS 110
- 2.11 SECONDARY SOURCES 111
- 2.12 ASSUMPTIONS 111
3 EXECUTIVE SUMMARY 112
4 PREMIUM INSIGHTS 115
- 4.1 PESTEL ANALYSIS 118
- 4.2 PORTER'S FIVE FORCES MODEL 119
5 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 120
6 EPIDEMIOLOGY 122
7 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 123
8 MARKET OVERVIEW 126
- 8.1 DRIVERS 128
- 8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER 128
- 8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 128
- 8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 129
- 8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 129
- 8.2 RESTRAINTS 130
- 8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS 130
- 8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 130
- 8.3 OPPORTUNITIES 131
- 8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 131
- 8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 132
- 8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 132
- 8.4 CHALLENGES 133
- 8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 133
- 8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 133
9 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 134
- 9.1 OVERVIEW 135
- 9.2 IMAGING TEST 138
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 139
- 9.2.2 MAGNETIC RESONANCE IMAGING (MRI) 139
- 9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY 139
- 9.2.2.2 MR ANGIOGRAPHY (MRA) 140
- 9.2.3 ULTRASOUND 140
- 9.2.3.1 ABDOMINAL ULTRASOUND 140
- 9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS) 140
- 9.2.4 CHOLANGIOPANCREATOGRAPHY 140
- 9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 141
- 9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 141
- 9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 141
- 9.2.5 POSITRON EMISSION TOMOHRAPHY (PET) 141
- 9.2.6 OTHERS 141
- 9.3 BIOPSY 142
- 9.3.1 CT-GUIDED NEEDLE BIOPSY 143
- 9.3.2 FINE NEEDLE ASPIRATION (FNA) 143
- 9.3.3 CORE NEEDLE BIOPSY 143
- 9.3.4 OTHERS 143
- 9.4 BLOOD TEST 143
- 9.4.1 LIVER FUNCTION TEST 144
- 9.4.2 TUMOR MARKER 144
- 9.4.2.1 CA 19-9 BIOMARKER TEST 145
- 9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 145
- 9.4.2.3 CA 50 MARKER TEST 145
- 9.4.2.4 OTHERS 145
- 9.4.3 OTHERS 145
- 9.5 GENOMIC TEST 146
- 9.6 OTHERS 147
10 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 148
- 10.1 OVERVIEW 149
- 10.2 STAGE IV 152
- 10.3 STAGE III 152
- 10.4 STAGE II 153
- 10.4.1 STAGE IIA 154
- 10.4.2 STAGE IIB 154
- 10.5 STAGE I 154
- 10.5.1 STAGE IA 155
- 10.5.2 STAGE IB 155
- 10.6 STAGE 0 156
11 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 157
- 11.1 OVERVIEW 158
- 11.2 EXOCRINE TUMORS 161
- 11.2.1 INSTRUMENT-BASED PRODUCTS 162
- 11.2.2 PLATFORM-BASED PRODUCTS 162
- 11.2.3 KITS AND REAGENTS 162
- 11.2.4 OTHER CONSUMABLES 162
- 11.3 NEUROENDOCRINE TUMORS 162
- 11.3.1 INSTRUMENT-BASED PRODUCTS 163
- 11.3.2 PLATFORM-BASED PRODUCTS 163
- 11.3.3 KITS AND REAGENTS 164
- 11.3.4 OTHER CONSUMABLES 164
12 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 165
- 12.1 OVERVIEW 166
- 12.2 INSTRUMENT-BASED PRODUCTS 169
- 12.2.1 IMAGING 170
- 12.2.2 BIOPSY 170
- 12.3 PLATFORM-BASED PRODUCTS 170
- 12.3.1 NEXT-GENERATION SEQUENCING 171
- 12.3.2 MICROARRAYS 171
- 12.3.3 PCR 171
- 12.3.4 OTHERS 172
- 12.4 KITS AND REAGENTS 172
- 12.4.1 CA19-9 PANCREATIC CANCER TEST KITS 173
- 12.4.1.1 ELISA TEST KITS 173
- 12.4.1.2 CASETTE TEST KITS 173
- 12.4.1.3 OTHERS 173
- 12.4.2 CEA PANCREATIC CANCER TEST KITS 174
- 12.4.2.1 ELISA TEST KITS 174
- 12.4.2.2 CASETTE TEST KITS 174
- 12.4.2.3 OTHERS 174
- 12.4.1 CA19-9 PANCREATIC CANCER TEST KITS 173
- 12.5 OTHER CONSUMABLES 174
13 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 176
- 13.1 OVERVIEW 177
- 13.2 FLUORESCENT IN SITU HYBRIDIZATION 180
- 13.3 NEXT GENERATION SEQUENCING 181
- 13.4 FLUORIMMUNOASSAY 182
- 13.5 COMPARATIVE GENOMIC HYBRIDIZATION 183
- 13.6 IMMUNOHISTOCHEMICAL 184
- 13.7 OTHERS 185
14 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 186
- 14.1 OVERVIEW 187
- 14.2 SCREENING 190
- 14.2.1 INSTRUMENT-BASED PRODUCTS 191
- 14.2.2 PLATFORM-BASED PRODUCTS 191
- 14.2.3 KITS AND REAGENTS 191
- 14.2.4 OTHER CONSUMABLES 191
- 14.3 DIAGNOSTIC AND PREDICTIVE 191
- 14.3.1 INSTRUMENT-BASED PRODUCTS 192
- 14.3.2 PLATFORM-BASED PRODUCTS 192
- 14.3.3 KITS AND REAGENTS 192
- 14.3.4 OTHER CONSUMABLES 192
- 14.4 PROGNOSTIC 193
- 14.4.1 INSTRUMENT-BASED PRODUCTS 194
- 14.4.2 PLATFORM-BASED PRODUCTS 194
- 14.4.3 KITS AND REAGENTS 194
- 14.4.4 OTHER CONSUMABLES 194
- 14.5 RESEARCH 194
- 14.5.1 INSTRUMENT-BASED PRODUCTS 195
- 14.5.2 PLATFORM-BASED PRODUCTS 195
- 14.5.3 KITS AND REAGENTS 195
- 14.5.4 OTHER CONSUMABLES 195
15 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 196
- 15.1 OVERVIEW 197
- 15.2 HOSPITALS 200
- 15.3 DIAGNOSTIC CENTERS 200
- 15.4 CANCER RESEARCH CENTERS 201
- 15.5 ACADEMIC INSTITUTES 202
- 15.6 AMBULATORY SURGICAL CENTERS 203
- 15.7 OTHERS 204
16 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 205
- 16.1 OVERVIEW 206
- 16.2 DIRECT TENDER 209
- 16.3 RETAIL SALES 210
- 16.4 OTHERS 211
17 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 212
- 17.1 OVERVIEW 213
- 17.2 NORTH AMERICA 219
- 17.2.1 U.S. 233
- 17.2.2 CANADA 242
- 17.2.3 MEXICO 251
- 17.3 EUROPE 260
- 17.3.1 GERMANY 275
- 17.3.2 FRANCE 284
- 17.3.3 UNITED KINGDOM 293
- 17.3.4 ITALY 302
- 17.3.5 SPAIN 311
- 17.3.6 RUSSIA 320
- 17.3.7 NETHERLANDS 329
- 17.3.8 POLAND 338
- 17.3.9 SWITZERLAND 347
- 17.3.10 BELGIUM 356
- 17.3.11 SWEDEN 365
- 17.3.12 NORWAY 374
- 17.3.13 DENMARK 383
- 17.3.14 FINLAND 392
- 17.3.15 TURKEY 401
- 17.3.16 REST OF EUROPE 410
- 17.4 ASIA-PACIFIC 411
- 17.4.1 CHINA 424
- 17.4.2 JAPAN 432
- 17.4.3 INDIA 440
- 17.4.4 SOUTH KOREA 448
- 17.4.5 AUSTRALIA 456
- 17.4.6 TAIWAN 464
- 17.4.7 NEW ZEALAND 472
- 17.4.8 INDONESIA 480
- 17.4.9 THAILAND 488
- 17.4.10 PHILIPPINES 496
- 17.4.11 MALAYSIA 504
- 17.4.12 VIETNAM 512
- 17.4.13 SINGAPORE 520
- 17.4.14 REST OF ASIA-PACIFIC 528
- 17.5 SOUTH AMERICA 529
- 17.5.1 BRAZIL 542
- 17.5.2 ARGENTINA 550
- 17.5.3 REST OF SOUTH AMERICA 558
- 17.6 MIDDLE EAST AND AFRICA 559
- 17.6.1 SOUTH AFRICA 574
- 17.6.2 SAUDI ARABIA 583
- 17.6.3 BAHRAIN 592
- 17.6.4 UAE 601
- 17.6.5 EGYPT 610
- 17.6.6 ISRAEL 619
- 17.6.7 KUWAIT 628
- 17.6.8 OMAN 637
- 17.6.9 QATAR 646
- 17.6.10 REST OF MIDDLE EAST AND AFRICA 655
18 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 656
- 18.1 COMPANY SHARE ANALYSIS: GLOBAL 656
- 18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 657
- 18.3 COMPANY SHARE ANALYSIS: EUROPE 658
- 18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 659
19 SWOT ANALYSIS 660
20 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET 661
- 20.1 CANON MEDICAL SYSTEMS CORPORATION 661
- 20.1.1 COMPANY SNAPSHOT 661
- 20.1.2 REVENUE ANALYSIS 661
- 20.1.3 COMPANY SHARE ANALYSIS 662
- 20.1.4 PRODUCT PORTFOLIO 662
- 20.1.5 RECENT DEVELOPMENT 662
- 20.2 KONINKLIJKE PHILIPS N.V. 663
- 20.2.1 COMPANY SNAPSHOT 663
- 20.2.2 REVENUE ANALYSIS 663
- 20.2.3 COMPANY SHARE ANALYSIS 664
- 20.2.4 PRODUCT PORTFOLIO 664
- 20.2.5 RECENT DEVELOPMENTS 664
- 20.3 SIEMENS HEALTHCARE GMBH 666
- 20.3.1 COMPANY SNAPSHOT 666
- 20.3.2 REVENUE ANALYSIS 666
- 20.3.3 COMPANY SHARE ANALYSIS 667
- 20.3.4 PRODUCT PORTFOLIO 667
- 20.3.5 RECENT DEVELOPMENT 668
- 20.4 GRAIL 669
- 20.4.1 COMPANY PROFILE 669
- 20.4.2 COMPANY SHARE ANALYSIS 669
- 20.4.3 PRODUCT PORTFOLIO 670
- 20.4.4 RECENT DEVELOPMENT 670
- 20.5 MYRIAD GENETICS, INC. 671
- 20.5.1 COMPANY SNAPSHOT 671
- 20.5.2 REVENUE ANALYSIS 671
- 20.5.3 COMPANY SHARE ANALYSIS 672
- 20.5.4 PRODUCT PORTFOLIO 672
- 20.5.5 RECENT DEVELOPMENT 672
- 20.6 BD 673
- 20.6.1 COMPANY SNAPSHOT 673
- 20.6.2 REVENUE ANALYSIS 673
- 20.6.3 PRODUCT PORTFOLIO 674
- 20.6.4 RECENT DEVELOPMENT 674
- 20.7 BODITECH MED INC. 675
- 20.7.1 COMPANY PROFILE 675
- 20.7.2 PRODUCT PORTFOLIO 675
- 20.7.3 RECENT DEVELOPMENT 675
- 20.8 ABBOTT (2022) 676
- 20.8.1 COMPANY SNAPSHOT 676
- 20.8.2 REVENUE ANALYSIS 676
- 20.8.3 PRODUCT PORTFOLIO 677
- 20.8.4 RECENT DEVELOPMENT 677
- 20.9 FUJIFILM HOLDINGS AMERICA CORPORATION 678
- 20.9.1 COMPANY SNAPSHOT 678
- 20.9.2 REVENUE ANALYSIS 678
- 20.9.3 PRODUCT PORTFOLIO 679
- 20.9.4 RECENT DEVELOPMENT 679
- 20.10 ACCUBIOTECH CO., LTD. 680
- 20.10.1 COMPANY PROFILE 680
- 20.10.2 PRODUCT PORTFOLIO 680
- 20.10.3 RECENT DEVELOPMENTS 680
- 20.11 AGILENT TECHNOLOGIES, INC. 681
- 20.11.1 COMPANY PROFILE 681
- 20.11.2 REVENUE ANALYSIS 681
- 20.11.3 PRODUCT PORTFOLIO 682
- 20.11.4 RECENT DEVELOPMENT 682
- 20.12 CREATIVE BIOLABS. 683
- 20.12.1 COMPANY PROFILE 683
- 20.12.2 PRODUCT PORTFOLIO 683
- 20.12.3 RECENT DEVELOPMENT 683
- 20.13 CTK BIOTECH, INC. 684
- 20.13.1 COMPANY PROFILE 684
- 20.13.2 PRODUCT PORTFOLIO 684
- 20.13.3 RECENT DEVELOPMENT 684
- 20.14 DIASOURCE 685
- 20.14.1 COMPANY SNAPSHOT 685
- 20.14.2 PRODUCT PORTFOLIO 685
- 20.14.3 RECENT DEVELOPMENT 685
- 20.15 LABORATORY CORPORATION OF AMERICA HOLDINGS 686
- 20.15.1 COMPANY SNAPSHOT 686
- 20.15.2 REVENUE ANALYSIS 686
- 20.15.3 PRODUCT PORTFOLIO 687
- 20.15.4 RECENT DEVELOPMENTS 687
- 20.16 LEE BIOSCIENCE 688
- 20.16.1 COMPANY SNAPSHOT 688
- 20.16.2 PRODUCT PORTFOLIO 688
- 20.16.3 RECENT DEVELOPMENT 688
- 20.17 MERIDIAN BIOSCIENCE INC. 689
- 20.17.1 COMPANY PROFILE 689
- 20.17.2 PRODUCT PORTFOLIO 689
- 20.17.3 RECENT DEVELOPMENT 689
- 20.18 MP BIOMEDICALS. 690
- 20.18.1 COMPANY PROFILE 690
- 20.18.2 PRODUCT PORTFOLIO 690
- 20.18.3 RECENT DEVELOPMENTS 690
- 20.19 QIAGEN 691
- 20.19.1 COMPANY SNAPSHOT 691
- 20.19.2 REVENUE ANALYSIS 691
- 20.19.3 PRODUCT PORTFOLIO 692
- 20.19.4 RECENT DEVELOPMENT 692
- 20.20 SETIA SCIENTIFIC SOLUTION 693
- 20.20.1 COMPANY PROFILE 693
- 20.20.2 PRODUCT PORTFOLIO 693
- 20.20.3 RECENT DEVELOPMENTS 693
- 20.21 THERMO FISHER SCIENTIFIC INC. 694
- 20.21.1 COMPANY SNAPSHOT 694
- 20.21.2 REVENUE ANALYSIS 694
- 20.21.3 PRODUCT PORTFOLIO 695
- 20.21.4 RECENT DEVELOPMENT 695
21 QUESTIONNAIRE 696
22 RELATED REPORTS 700
LIST OF TABLES
- TABLE 1 APPROVED DIAGNOSTICS OF PANCREATIC CANCER 131
- TABLE 2 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
- TABLE 3 GLOBAL IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 138
- TABLE 4 GLOBAL IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 139
- TABLE 5 GLOBAL MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 139
- TABLE 6 GLOBAL ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
- TABLE 7 GLOBAL CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 141
- TABLE 8 GLOBAL BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 142
- TABLE 9 GLOBAL BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
- TABLE 10 GLOBAL BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 144
- TABLE 11 GLOBAL BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 144
- TABLE 12 GLOBAL TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 145
- TABLE 13 GLOBAL GENOMIC TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
- TABLE 14 GLOBAL OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 147
- TABLE 15 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 151
- TABLE 16 GLOBAL STAGE IV IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 152
- TABLE 17 GLOBAL STAGE III IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 153
- TABLE 18 GLOBAL STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 154
- TABLE 19 GLOBAL STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 154
- TABLE 20 GLOBAL STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 155
- TABLE 21 GLOBAL STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 155
- TABLE 22 GLOBAL STAGE 0 IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 156
- TABLE 23 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 160
- TABLE 24 GLOBAL EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 161
- TABLE 25 GLOBAL EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 162
- TABLE 26 GLOBAL NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 163
- TABLE 27 GLOBAL NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 163
- TABLE 28 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 168
- TABLE 29 GLOBAL INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 169
- TABLE 30 GLOBAL INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 170
- TABLE 31 GLOBAL PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 171
- TABLE 32 GLOBAL PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 171
- TABLE 33 GLOBAL KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 172
- TABLE 34 GLOBAL KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
- TABLE 35 GLOBAL CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
- TABLE 36 GLOBAL CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 174
- TABLE 37 GLOBAL OTHER CONSUMABLES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 175
- TABLE 38 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 179
- TABLE 39 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 180
- TABLE 40 GLOBAL NEXT GENERATION SEQUENCING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 181
- TABLE 41 GLOBAL FLUORIMMUNOASSAY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 182
- TABLE 42 GLOBAL COMPARATIVE GENOMIC HYBRIDIZATION IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 183
- TABLE 43 GLOBAL IMMUNOHISTOCHEMICAL IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 184
- TABLE 44 GLOBAL OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 185
- TABLE 45 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 189
- TABLE 46 GLOBAL SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 190
- TABLE 47 GLOBAL SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 190
- TABLE 48 GLOBAL DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 192
- TABLE 49 GLOBAL DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 192
- TABLE 50 GLOBAL PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 193
- TABLE 51 GLOBAL PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 193
- TABLE 52 GLOBAL RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 195
- TABLE 53 GLOBAL RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 195
- TABLE 54 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 199
- TABLE 55 GLOBAL HOSPITALS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 200
- TABLE 56 GLOBAL DIAGNOSTIC CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 201
- TABLE 57 GLOBAL CANCER RESEARCH CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 201
- TABLE 58 GLOBAL ACADEMIC INSTITUTES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 202
- TABLE 59 GLOBAL AMBULATORY SURGICAL CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 203
- TABLE 60 GLOBAL OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 204
- TABLE 61 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 208
- TABLE 62 GLOBAL DIRECT TENDER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 209
- TABLE 63 GLOBAL RETAIL SALES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 210
- TABLE 64 GLOBAL OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 211
- TABLE 65 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 218
- TABLE 66 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 224
- TABLE 67 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 224
- TABLE 68 NORTH AMERICA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 225
- TABLE 69 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 225
- TABLE 70 NORTH AMERICA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 225
- TABLE 71 NORTH AMERICA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 225
- TABLE 72 NORTH AMERICA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 226
- TABLE 73 NORTH AMERICA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 226
- TABLE 74 NORTH AMERICA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 226
- TABLE 75 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 226
- TABLE 76 NORTH AMERICA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 227
- TABLE 77 NORTH AMERICA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 227
- TABLE 78 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 227
- TABLE 79 NORTH AMERICA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 227
- TABLE 80 NORTH AMERICA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 228
- TABLE 81 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 228
- TABLE 82 NORTH AMERICA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 228
- TABLE 83 NORTH AMERICA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 228
- TABLE 84 NORTH AMERICA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 229
- TABLE 85 NORTH AMERICA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 229
- TABLE 86 NORTH AMERICA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 229
- TABLE 87 NORTH AMERICA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 229
- TABLE 88 NORTH AMERICA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 230
- TABLE 89 NORTH AMERICA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 230
- TABLE 90 NORTH AMERICA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 230
- TABLE 91 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 230
- TABLE 92 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 231
- TABLE 93 NORTH AMERICA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 231
- TABLE 94 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 231
- TABLE 95 NORTH AMERICA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 231
- TABLE 96 NORTH AMERICA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 232
- TABLE 97 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 232
- TABLE 98 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 232
- TABLE 99 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 233
- TABLE 100 U.S. IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 233
- TABLE 101 U.S. MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 233
- TABLE 102 U.S. ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 234
- TABLE 103 U.S. CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 234
- TABLE 104 U.S. BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 234
- TABLE 105 U.S. TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 234
- TABLE 106 U.S. BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 235
- TABLE 107 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 235
- TABLE 108 U.S. STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 235
- TABLE 109 U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 235
- TABLE 110 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 236
- TABLE 111 U.S. EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 236
- TABLE 112 U.S. NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 236
- TABLE 113 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 236
- TABLE 114 U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 237
- TABLE 115 U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 237
- TABLE 116 U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 237
- TABLE 117 U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 237
- TABLE 118 U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 237
- TABLE 119 U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 238
- TABLE 120 U.S. KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 238
- TABLE 121 U.S. CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 238
- TABLE 122 U.S. CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 238
- TABLE 123 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 239
- TABLE 124 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 239
- TABLE 125 U.S. SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 239
- TABLE 126 U.S. DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 240
- TABLE 127 U.S. PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 240
- TABLE 128 U.S. RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 240
- TABLE 129 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 241
- TABLE 130 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 241
- TABLE 131 CANADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 242
- TABLE 132 CANADA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 242
- TABLE 133 CANADA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 242
- TABLE 134 CANADA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 243
- TABLE 135 CANADA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 243
- TABLE 136 CANADA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 243
- TABLE 137 CANADA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 243
- TABLE 138 CANADA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 244
- TABLE 139 CANADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 244
- TABLE 140 CANADA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 244
- TABLE 141 CANADA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 244
- TABLE 142 CANADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 245
- TABLE 143 CANADA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 245
- TABLE 144 CANADA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 245
- TABLE 145 CANADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 245
- TABLE 146 CANADA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 246
- TABLE 147 CANADA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 246
- TABLE 148 CANADA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 246
- TABLE 149 CANADA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 246
- TABLE 150 CANADA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 246
- TABLE 151 CANADA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 247
- TABLE 152 CANADA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 247
- TABLE 153 CANADA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 247
- TABLE 154 CANADA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 247
- TABLE 155 CANADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 248
- TABLE 156 CANADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 248
- TABLE 157 CANADA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 248
- TABLE 158 CANADA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 249
- TABLE 159 CANADA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 249
- TABLE 160 CANADA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 249
- TABLE 161 CANADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 250
- TABLE 162 CANADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 250
- TABLE 163 MEXICO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 251
LIST OF FIGURES
- FIGURE 1 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION 99
- FIGURE 2 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 102
- FIGURE 3 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 103
- FIGURE 4 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 104
- FIGURE 5 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 104
- FIGURE 6 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 105
- FIGURE 7 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 107
- FIGURE 8 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 109
- FIGURE 9 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 110
- FIGURE 10 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION 114
- FIGURE 11 GROWING AWARENESS OF PANCREATIC CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030 115
- FIGURE 12 IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030 115
- FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET, AND NORTH AMERICA IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 116
- FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR PANCREATIC CANCER DIAGNOSTIC MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 117
- FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET 127
- FIGURE 16 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 135
- FIGURE 17 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 136
- FIGURE 18 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 136
- FIGURE 19 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 137
- FIGURE 20 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2022 149
- FIGURE 21 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2023-2030 (USD MILLION) 150
- FIGURE 22 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, CAGR (2023-2030) 150
- FIGURE 23 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, LIFELINE CURVE 151
- FIGURE 24 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2022 158
- FIGURE 25 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION) 159
- FIGURE 26 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, CAGR (2023-2030) 159
- FIGURE 27 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, LIFELINE CURVE 160
- FIGURE 28 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022 166
- FIGURE 29 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION) 167
- FIGURE 30 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030) 167
- FIGURE 31 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE 168
- FIGURE 32 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022 177
- FIGURE 33 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 178
- FIGURE 34 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030) 178
- FIGURE 35 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE 179
- FIGURE 36 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022 187
- FIGURE 37 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 188
- FIGURE 38 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030) 188
- FIGURE 39 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE 189
- FIGURE 40 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022 197
- FIGURE 41 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 198
- FIGURE 42 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 198
- FIGURE 43 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 199
- FIGURE 44 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 206
- FIGURE 45 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 207
- FIGURE 46 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 207
- FIGURE 47 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 208
- FIGURE 48 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 214
- FIGURE 49 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY REGION (2022) 216
- FIGURE 50 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY REGION (2023 & 2030) 216
- FIGURE 51 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY REGION (2022 & 2030) 217
- FIGURE 52 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE (2023-2030) 217
- FIGURE 53 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 220
- FIGURE 54 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 222
- FIGURE 55 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 222
- FIGURE 56 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 223
- FIGURE 57 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: CATEGORY (2023-2030) 223
- FIGURE 58 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 261
- FIGURE 59 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 263
- FIGURE 60 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 263
- FIGURE 61 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 264
- FIGURE 62 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE (2023-2030) 264
- FIGURE 63 ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 412
- FIGURE 64 ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 414
- FIGURE 65 ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 414
- FIGURE 66 ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 415
- FIGURE 67 ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE (2023-2030) 415
- FIGURE 68 SOUTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 530
- FIGURE 69 SOUTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 532
- FIGURE 70 SOUTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 532
- FIGURE 71 SOUTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 533
- FIGURE 72 SOUTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: CATEGORY (2023-2030) 533
- FIGURE 73 MIDDLE EAST AND AFRICA PANCREATIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 560
- FIGURE 74 MIDDLE EAST AND AFRICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 562
- FIGURE 75 MIDDLE EAST AND AFRICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 562
- FIGURE 76 MIDDLE EAST AND AFRICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 563
- FIGURE 77 MIDDLE EAST AND AFRICA PANCREATIC CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 563
- FIGURE 78 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 656
- FIGURE 79 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 657
- FIGURE 80 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 658
- FIGURE 81 ASIA-PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 659
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.